Manifestations of virus-specific antigens in virus-induced tumor cells. Theoretical and practical considerations.

R. Huebner

Abstract:

What problem does this paper attempt to address?

'Moral panics' and asylum seekers.

M. Johnstone

2015-09-01

Abstract:Desperate human beings - men, women and children - seeking asylum in Australia have been portrayed by conservative politicians and a cadre of equally conservative journalists as 'illegals', 'immoral queue jumpers', and a 'threat to our cherished way of life' when in reality they are none of these things (Leach, 2003).
Treatment of lysosomal storage disorders: Cell therapy and gene therapy

Y. Eto,Jinsong Shen,Xing‐Li Meng,T. Ohashi

DOI: https://doi.org/10.1023/B:BOLI.0000031170.69676.68

IF: 4.7501

2004-05-01

Journal of Inherited Metabolic Disease

Abstract:
A novel quantum-inspired genetic algorithm for a weekly university scheduling optimization

Yu Zheng,Jingfa Liu

DOI: https://doi.org/10.1109/ICIST.2011.5765270

2011-03-26

Abstract:This paper presents a novel quantum-inspired algorithm(QGA) for the heavily constrained university scheduling problems(CUSP). The CUSP is a common problem for all institutions of higher education. It has been proved a NP problems. We propose a solving of CUSP based on the use of quantum-inspired algorithms. In the QGA, Q-bits based representation is employed by updating operator of quantum gate which is introduced as a variation operator to drive the individuals toward better solutions. The experimental results show that a set of high quality timetables can be achieved.
Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors

Mohamad Wessam Alnouri,Stephan Jepards,Alessandro Casari,Anke C Schiedel,Sonja Hinz,Christa E Müller

DOI: https://doi.org/10.1007/s11302-015-9460-9

Abstract:Adenosine receptors (ARs) have emerged as new drug targets. The majority of data on affinity/potency and selectivity of AR ligands described in the literature has been obtained for the human species. However, preclinical studies are mostly performed in mouse or rat, and standard AR agonists and antagonists are frequently used for studies in rodents without knowing their selectivity in the investigated species. In the present study, we selected a set of frequently used standard AR ligands, 8 agonists and 16 antagonists, and investigated them in radioligand binding studies at all four AR subtypes, A1, A2A, A2B, and A3, of three species, human, rat, and mouse. Recommended, selective agonists include CCPA (for A1AR of rat and mouse), CGS-21680 (for A2A AR of rat), and Cl-IB-MECA (for A3AR of all three species). The functionally selective partial A2B agonist BAY60-6583 was found to additionally bind to A1 and A3AR and act as an antagonist at both receptor subtypes. The antagonists PSB-36 (A1), preladenant (A2A), and PSB-603 (A2B) displayed high selectivity in all three investigated species. MRS-1523 acts as a selective A3AR antagonist in human and rat, but is only moderately selective in mouse. The comprehensive data presented herein provide a solid basis for selecting suitable AR ligands for biological studies.
Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Stefania Gessi,Katia Varani,Stefania Merighi,Edward Leung,Stephen Mac Lennan,Pier Giovanni Baraldi,Pier Andrea Borea

DOI: https://doi.org/10.1007/s11302-006-9019-x

2006-07-08

Purinergic Signalling

Abstract:The adenosine A2B receptor is the least well characterized of the four adenosine subtypes due to the lack of potent and selective agonists and antagonists. Despite the widespread distribution of A2B receptor mRNA, little information is available with regard to their function. The characterization of A2B receptors, through radioligand binding studies, has been performed, until now, by using low-affinity and non-selective antagonists like 1,3-dipropyl-8-cyclopentylxanthine ([3H]DPCPX),(4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-ylamino]ethyl)-phenol ([3H]ZM 241385) and 3-(3,4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propyl-xanthine ([125I]ABOPX). Recently, high-affinity radioligands for A2B receptors, [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]acetamide ([3H]MRS 1754), N-(2-(2-Phenyl-6-[4-(2,2,3,3-tetratritrio-3-phenylpropyl)-piperazine-1-carbonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ethyl)-acetamide ([3H]OSIP339391) and N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide] ([3H]MRE 2029F20), have been introduced. This minireview offers an overview of these recently developed radioligands and the most important applications of drugs towards A2B receptors.

neurosciences
Eccentricity and spin-orbit misalignment in short-period stellar binaries as a signpost of hidden tertiary companions

Kassandra R. Anderson,D. Lai,Natalia I. Storch

DOI: https://doi.org/10.1093/mnras/stx293

2016-10-09

Abstract:Eclipsing binaries are observed to have a range of eccentricities and spin-orbit misalignments (stellar obliquities). Whether such properties are primordial or arise from post-formation dynamical interactions remains uncertain. This paper considers the scenario in which the binary is the inner component of a hierarchical triple stellar system, and derives the requirements that the tertiary companion must satisfy in order to raise the eccentricity and obliquity of the inner binary. Through numerical integrations of the secular octupole-order equations of motion of stellar triples, coupled with the spin precession of the oblate primary star due to the torque from the secondary, we obtain a simple, robust condition for producing spin-orbit misalignment in the inner binary. In order to excite appreciable obliquity, the precession rate of the stellar spin axis must be smaller than the orbital precession rate due to the tertiary companion. This yields quantitative requirements on the mass and orbit of the tertiary. We also present new analytic expressions for the maximum eccentricity and range of inclinations allowing eccentricity excitation (Lidov–Kozai window), for stellar triples with arbitrary masses and including the non-Keplerian potentials introduced by general relativity, stellar tides and rotational bulges. The results of this paper can be used to place constraints on unobserved tertiary companions in binaries that exhibit high eccentricity and/or spin-orbit misalignment, and will be helpful in guiding efforts to detect external companions around stellar binaries. As an application, we consider the eclipsing binary DI Herculis, and identify the requirements that a tertiary companion must satisfy to produce the observed spin-orbit misalignment.
Characterization and partial purification of a lipase from Pseudomonas aeruginosa.

A. Finkelstein,E. Strawich,S. Sonnino

DOI: https://doi.org/10.1016/0005-2744(70)90154-3

1970-06-10

Biochimica et Biophysica Acta

Abstract:
Adenosine antagonists as potential therapeutic agents

M Williams,M F Jarvis

DOI: https://doi.org/10.1016/0091-3057(88)90182-7

Abstract:The methylxanthine caffeine has been identified in more than 60 plant species and has been in human use for its various therapeutic actions for many hundreds of years and perhaps, with the exception of aspirin and related compounds, is the most widely consumed drug today. Pharmacologically, the xanthines are prototypic inhibitors of the enzyme, cyclic nucleotide phosphodiesterase, are calcium mobilizers and have been reported to inhibit the enzymes, monoamine oxidase and cyclooxygenase as well as affect uptake of the putative neuromodulator, adenosine. However, many of the therapeutic effects ascribed to caffeine are due to its selective ability to antagonize the actions of adenosine. Many xanthines, especially those substituted in the 8-position with a phenyl derivative, are potent and selective adenosine antagonists. The xanthine adenosine antagonists have mild psychostimulant, analgesic adjuvant, diuretic, cardiotonic and antiasthmatic activity. Adenosine antagonists also have nootropic activity. A major limiting factor to the development of this class of compound has been in the lack of selectivity for either of the major classes of adenosine receptor. Several non-xanthines including the pyrazolopyrimidine, DJB-KK, the pyrazoloquinoline, CGS 8216 and the pyrazolopyridine, etazolate have been shown to have adenosine antagonist activity. The triazoloquinazoline, CGS 15943 A has been identified as the first, potent (IC50 = 3 nM) nonxanthine, A2-selective adenosine antagonist while the phenylquinazoline, HTQZ, has 25-fold selectivity for the A2 receptor. The availability of such novel entities may permit the development of a new class of therapeutic agents able to affect neuromodulator, as opposed to neurotransmitter, function.
Medicinal chemistry of adenosine A3 receptor ligands

Christa E Müller

DOI: https://doi.org/10.2174/1568026033392174

Abstract:A(3) Adenosine receptors (ARs) exhibit large species differences. Potent, selective agonists for rat (e.g. Cl-IB-MECA, 5) and human A(3) ARs (e.g. PENECA, 17, and analogs) have been developed during the past years. Potent, selective antagonists for human A(3) ARs include the imidazopurinones PSB-10 (28) and PSB-11 (29), the pyrazolotriazolopyrimidines MRE-3005F20 (38) and analogs, and the dihydropyridines (e.g. MRS-1334, 50). For rat A(3) ARs only moderately potent antagonists have been identified, such as the pyridine derivative MRS-1523 (51) and the flavonoid MRS-1067 (52), both of which exhibit only a low degree of selectivity versus the other AR subtypes. Selective antagonist radioligands for the human A(3) receptor, [(3)H]MRE-3008F20 and [(3)H]PSB-11, have been prepared, while A(3)-selective agonist radioligands are still lacking. Recent developments also include allosteric modulators, irreversibly binding antagonists, fluorescence-labelled agonists, partial agonists and inverse agonists for A(3)ARs. Site-directed mutagenesis and molecular modeling studies have been performed in order to obtain information about the ligand binding site and the process of receptor activation. A(3)Adenosine receptors have recently attracted considerable interest as novel drug targets. A(3) Agonists may have potential as cardioprotective and cerebroprotective agents, for the treatment of asthma, as antiinflammatory and immunosuppressive agents, and in cancer therapy as cytostatics and chemoprotective compounds. A(3) AR antagonists might be therapeutically useful for the acute treatment of stroke, for glaucoma, and also as antiasthmatic and antiallergic drugs, since A(3)receptors cannot only mediate antiinflammatory, but also proinflammatory responses. The future development of further pharmacological tools, including potent, selective antagonists for rat A(3) receptors and selective agonist radioligands for rat and human receptors will facilitate the evaluation of the (patho)physiological roles of A(3) receptors and the pharmacological potential of their ligands.
2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

Filipe Areias,Carla Correia,Ashly Rocha,Sofia Teixeira,Marián Castro,Jose Brea,Huabin Hu,Jens Carlsson,Maria I. Loza,M. Fernanda Proença,M. Alice Carvalho

DOI: https://doi.org/10.3390/molecules29112543

IF: 4.6

2024-05-29

Molecules

Abstract:A set of 2-aryl-9-H or methyl-6-morpholinopurine derivatives were synthesized and assayed through radioligand binding tests at human A1, A2A, A2B, and A3 adenosine receptor subtypes. Eleven purines showed potent antagonism at A1, A3, dual A1/A2A, A1/A2B, or A1/A3 adenosine receptors. Additionally, three compounds showed high affinity without selectivity for any specific adenosine receptor. The structure-activity relationships were made for this group of new compounds. The 9-methylpurine derivatives were generally less potent but more selective, and the 9H-purine derivatives were more potent but less selective. These compounds can be an important source of new biochemical tools and/or pharmacological drugs.

chemistry, multidisciplinary,biochemistry & molecular biology
Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

Lili Du,Zhan-Guo Gao,Silvia Paoletta,Tina C Wan,Elizabeth T Gizewski,Samantha Barbour,Jacobus P D van Veldhoven,Adriaan P IJzerman,Kenneth A Jacobson,John A Auchampach

DOI: https://doi.org/10.1007/s11302-017-9592-1

Abstract:Activity of the A3 adenosine receptor (AR) allosteric modulators LUF6000 (2-cyclohexyl-N-(3,4-dichlorophenyl)-1H-imidazo [4,5-c]quinolin-4-amine) and LUF6096 (N-{2-[(3,4-dichlorophenyl)amino]quinolin-4-yl}cyclohexanecarbox-amide) was compared at four A3AR species homologs used in preclinical drug development. In guanosine 5'-[γ-[35S]thio]triphosphate ([35S]GTPγS) binding assays with cell membranes isolated from human embryonic kidney cells stably expressing recombinant A3ARs, both modulators substantially enhanced agonist efficacy at human, dog, and rabbit A3ARs but provided only weak activity at mouse A3ARs. For human, dog, and rabbit, both modulators increased the maximal efficacy of the A3AR agonist 2-chloro-N 6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide as well as adenosine > 2-fold, while slightly reducing potency in human and dog. Based on results from N 6-(4-amino-3-[125I]iodobenzyl)adenosine-5'-N-methylcarboxamide ([125I]I-AB-MECA) binding assays, we hypothesize that potency reduction is explained by an allosterically induced slowing in orthosteric ligand binding kinetics that reduces the rate of formation of ligand-receptor complexes. Mutation of four amino acid residues of the human A3AR to the murine sequence identified the extracellular loop 1 (EL1) region as being important in selectively controlling the allosteric actions of LUF6096 on [125I]I-AB-MECA binding kinetics. Homology modeling suggested interaction between species-variable EL1 and agonist-contacting EL2. These results indicate that A3AR allostery is species-dependent and provide mechanistic insights into this therapeutically promising class of agents.
Species dependence of A3 adenosine receptor pharmacology and function

Zhan-Guo Gao,John A. Auchampach,Kenneth A. Jacobson

DOI: https://doi.org/10.1007/s11302-022-09910-1

2022-12-21

Purinergic Signalling

Abstract:Efforts to fully understand pharmacological differences between G protein-coupled receptor (GPCR) species homologues are generally not pursued in detail during the drug development process. To date, many GPCRs that have been successfully targeted are relatively well-conserved across species in amino acid sequence and display minimal variability of biological effects. However, the A 3 adenosine receptor (AR), an exciting drug target for a multitude of diseases associated with tissue injury, ischemia, and inflammation, displays as little as 70% sequence identity among mammalian species (e.g., rodent vs. primate) commonly used in drug development. Consequently, the pharmacological properties of synthetic A 3 AR ligands vary widely, not only in binding affinity, selectivity, and signaling efficacy, but to the extent that some function as agonists in some species and antagonists in others. Numerous heterocyclic antagonists that have nM affinity at the human A 3 AR are inactive or weakly active at the rat and mouse A 3 ARs. Positive allosteric modulators, including the imidazo [4,5-c]quinolin-4-amine derivative LUF6000, are only active at human and some larger animal species that have been evaluated (rabbit and dog), but not rodents. A 3 AR agonists evoke systemic degranulation of rodent, but not human mast cells. The rat A 3 AR undergoes desensitization faster than the human A 3 AR, but the human homologue can be completely re-sensitized and recycled back to the cell surface. Thus, comprehensive pharmacological evaluation and awareness of potential A 3 AR species differences are critical in studies to further understand the basic biological functions of this unique AR subtype. Recombinant A 3 ARs from eight different species have been pharmacologically characterized thus far. In this review, we describe in detail current knowledge of species differences in genetic identity, G protein-coupling, receptor regulation, and both orthosteric and allosteric A 3 AR pharmacology.

neurosciences
Metals, orthopaedic implants, and risk of cancer

P. Pigatto,G. Guzzi,G. Severi

DOI: https://doi.org/10.1016/S0140-6736(07)60561-3

IF: 202.731

2007-04-07

The Lancet

Abstract:
Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors

B Johansson,V Georgiev,B B Fredholm

DOI: https://doi.org/10.1016/s0306-4522(97)00143-7

IF: 3.708

Neuroscience

Abstract:In adult rat brain, adenosine A2A receptors and dopamine D2 receptors are known to be located on the same cells where they interact in an antagonistic manner. In the present study we wanted to examine when this situation develops and compared the postnatal ontogeny of the binding of the adenosine A2A receptor agonist [3H]CGS 21680, the binding of the dopamine D1 receptor antagonist [3H]SCH 23390 and the dopamine D2 receptor antagonist [3H]raclopride. All three radioligands bound to the striatum at birth and this binding increased several-fold during the postnatal period. [3H]SCH 23390 binding developed first (mostly during the first week), followed by [3H]raclopride binding (first to third week) and [3H]CGS 21680 binding (only during second and third week). For all three radioligands the binding tended to decrease between 21 days and adulthood. This occurred earlier and was more pronounced in the globus pallidus than in the other examined structures. The increase in [3H]CGS 21680 binding from newborn to adult was mainly due to four-fold increase in the number of binding sites. The pharmacology of [3H]CGS 21680 binding to caudate-putamen was similar in newborn, one-week-old and adult animals, and was indicative of A2A receptors. The binding was inhibited by guanylyl imidodiphosphate at all ages, indicating that A2A receptors are G-protein-coupled already at birth. In contrast to the large increase in [3H]CGS 21680 binding, there was a decrease in the levels of A2A messenger RNA during the postnatal period in the caudate-putamen. In cerebral cortex [3H]CGS 21680 bound to a different site than the A2A receptor. From birth to adulthood cortical binding of [3H]CGS 21680 increased four-fold and that of the adenosine A1 agonist [3H]cyclohexyladenosine 19-fold. During early postnatal development [3H]SCH 23390 binding was higher in deep than in superficial cortical layers, but this difference disappeared in adult animals. There was binding of both [3H]CGS 21680 and [3H]cyclohexyladenosine to the olfactory bulb, suggesting a role of the two adenosine receptors in processing of olfactory information. [3H]CGS 21680 binding was present in the external plexiform layer and glomerular layer, and increased during development, but the density of binding sites was about one tenth of that seen in caudate putamen. [3H]cyclohexyladenosine showed a very different labelling pattern, resembling that observed with [3H]SCH 23390. Postnatal changes in adenosine receptors may explain age-dependent differences in stimulatory caffeine effects and endogenous protection against seizures. Since A2A receptors show a co-distribution with D2 receptors throughout development, caffeine may partly exert such actions by regulating the activity of D2 receptor-containing striatopallidal neurons.
Strain-related differences in adenosine receptor density and in behavioral sensitivity to adenosine analogs in mice

C Florio,A M Rosati,U Traversa,R Vertua

DOI: https://doi.org/10.1016/0091-3057(94)90420-0

Abstract:The behavioral effects of the adenosine agonists 5'-N-ethylcarboxamidoadenosine (NECA) was investigated in two strains of inbred mice, CD1 and CBA. NECA dose dependently reduced spontaneous locomotor activity with similar potency (ED50 = 36 +/- 1.5 and 36 +/- 1.1 nmol/kg IP for CBA and CD1 mice, respectively) and efficacy (> 90% at 100 nmol/kg) in the two strains. One nmol/kg NECA, an ineffective dose in CBA mice, exerted a significant stimulant action in CD1 mice. In saturation experiments, no differences were found in the density or in the affinity of striatal A2a receptors labeled with [3H]NECA. A strain-related difference was found in the density of striatal A1 receptors labeled with [3H]CCPA. In CBA mice, the Bmax value was 32% less than in CD1 mice (0.646 +/- 0.037 and 0.951 +/- 0.073 pmol bound/mg protein, respectively, p < 0.05). No differences in [3H]CCPA binding parameters were found in cortical and hippocampal membranes obtained from the two strains, whereas a higher density of A1 binding sites was found in the cerebellum of CBA mice. The present results show a close correlation between binding studies and the depressant action of NECA and present evidence for strain-related differences in regional distribution of central adenosine receptors and in behavioral response to purinergic drugs.
Postoperative cognitive decline: where art tau?

R. Eckenhoff,E. Planel

DOI: https://doi.org/10.1097/ALN.0b013e31824be8e1

IF: 8.986

2012-04-01

Anesthesiology

Abstract:
Neuroleptic Malignant Syndrome (NMS): What are the Genetic Factors?

S. Bamforth,J. Hall

DOI: https://doi.org/10.1177/070674378703200430

1987-05-01

Abstract:later the patient developed fever at 38.5°C while on haloperidol 30 mg/ day and diphenhydramine 75 mg/ day. He exhibited lead-pipe rigidity with severe diaphoresis, and the following day; the diagnosis of neuroleptic malignant syndrome was made with CPK above 6,000. His temperature raised at 39.6°C three days later with CPK of 7,250. The patient had to undergo intensive management for NMS (dantrolene) and later on for treatment of hemoglobinuria and massive pneumonia. Over the course of ten days, Mr. A. slowly recovered. We would like to emphasize the change in medication from procyclidine to diphenhydramine that occurred one week prior to the onset of hyperpyrexia. Slight agitation motivated this change of anticholinergic drugs. This change is most important as two other cases of NMS where diphenhydramine was used in combination with haloperidol have recently come to our attention. Although the pathogenesis ofthis disorder is still obscure, the dopamine blockade hypothesis remains the most accepted theory (2). It is possible that a short-lasting and low potency central anticholinergic substance such as diphenhydramine does not adequately counteract the dopamine blockade of haloperidol. Thus this change may lead to an imbalance between cholinergic and dopamine transmission (3) and induce the NMS in some cases. In our experience an appropriate control of EPS and especially rigidity could prevent the development of NMS in some patients.
Influence of diazepam, alpidem, zolpidem and zopiclone, on the response to adenosine of the guinea pig isolated trachea

ML Candenas,P. Devillier,E. Naline,C. Advenier

DOI: https://doi.org/10.1111/j.1472-8206.1991.tb00696.x

1991-02-01

Fundamental and Clinical Pharmacology

Abstract:It has been reported that dipyridamole and some benzodiazepines potentiate the responses to adenosine in peripheral organs and in particular in the guinea pig isolated atria or trachea by inhibition of adenosine uptake and/or metabolism. In this study, we have examined the sensitization of guinea pig isolated trachea to relaxant responses to adenosine produced by dipyridamole, diazepam and 3 compounds chemically unrelated to benzodiazepines but which display selective agonistic activity towards the central (zolpidem and zopiclone) or peripheral (alpidem) type benzodiazpine receptors. In preparations under spontaneous tone and in the absence of adenosine, dipyridamole (10(-5) M) and diazepam (10(-5)-10(-4) M), alpidem (3 x 10(-6) M-10(-5) M) and zopiclone (10(-6)-10(-4) M) induced a relaxation of the airway smooth muscle. In addition, dazepam (10(-4) M) attenuated the phasic response to histamine (10(-5) M). Dipyridamole (10(-5) M) and diazepam (10(-4) M) respectively produced a 56.2 and 32.4-fold potentiation of adenosine relaxant effects. Alpidem (10(-6)-10(-5) M), zolpidem (10(-6)-10(-4) M) and zopiclone (10(-6)-10(-4) M) were without any significant effect on the adenosine concentration-response curves. Moreover, alpidem, zolpidem, and zopiclone did not modify the 2-chloroadenosine dose-response curves nor the diazepam induced sensitization of adenosine-induced relaxation. In conclusion, adenosine sensitization of the guinea pig isolated trachea caused by diazepam might involve a peripheral benzodiazpine receptor subtype coupled to a nucleoside transporter system which is different from those recognized by compounds derived from the imidazopyridine series.

pharmacology & pharmacy
A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity

Dilip K Tosh,Veronica Salmaso,Ryan G Campbell,Harsha Rao,Amelia Bitant,Eline Pottie,Christophe P Stove,Naili Liu,Oksana Gavrilova,Zhan-Guo Gao,John A Auchampach,Kenneth A Jacobson,Dilip K. Tosh,Ryan G. Campbell,Christophe P. Stove,John A. Auchampach,Kenneth A. Jacobson

DOI: https://doi.org/10.1016/j.ejmech.2021.113983

IF: 7.088

2022-01-01

European Journal of Medicinal Chemistry

Abstract:Following our study of 4'-truncated (N)-methanocarba-adenosine derivatives that displayed unusually high mouse (m) A3AR affinity, we incorporated dopamine-related N6 substituents in the full agonist 5'-methylamide series. N6-(2-(4-Hydroxy-3-methoxy-phenyl)ethyl) derivative MRS7618 11 displayed Ki (nM) 0.563 at hA3AR (∼20,000-fold selective) and 1.54 at mA3AR. 2-Alkyl ethers maintained A3 affinity, but with less selectivity than 2-alkynes. Parallel functional assays of G protein-dependent and β-arrestin 2 (βarr2)-dependent pathways indicate these are full agonists but not biased. Through use of computational modeling, we hypothesized that phenyl OH/OMe groups interact with polar residues, particularly Gln261, on the mA3AR extracellular loops as the basis for the affinity enhancement. Although the pharmacokinetics indicated facile clearance of parent O-methyl catechol nucleosides 21 and 31, prolonged mA3AR activation in vivo was observed in a hypothermia model, suggested potential formation of active metabolites through demethylation. Selected analogues induced mouse hypothermia following i.p. injection, indicative of peripheral A3AR agonism in vivo.

chemistry, medicinal
Activation of multiple sites by adenosine analogues in the rat isolated aorta

D J Prentice,S M Hourani

DOI: https://doi.org/10.1111/j.1476-5381.1996.tb15567.x

Abstract:1. The presence of A2 receptors mediating relaxation in the rat isolated aorta has been previously demonstrated. However, agonist dependency of the degree of rightward shift elicited by 8-sulphophenyltheophylline (8-SPT) led to the suggestion that the population of receptors in this tissue is not a homogeneous one. In this study we have re-examined the effects of 8-SPT in the absence and presence of the NO synthase inhibitor L-NAME (NG-nitro-L-arginine methyl ester) and investigated antagonism of responses by the potent A2a receptor ligands PD 115,199 (N-[2-dimethylamino)ethyl]-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3 dipropyl-1H-purin-8-yl)) benzene sulphonamidexanthine), ZM 241385 (4-(2-[7-amino-2-(2-furyl) [1,2,4]-triazolo[2,3-a][1,3,5]triazin-5-yl amino]ethyl)phenol), and CGS 21680 (2-[p-(2-carboxyethyl)phenylamino]-5'-N-ethylcarboxamidoadenosine). We have also investigated the antagonist effects of BWA1433 (1,3-dipropyl-8-(4-acrylate)phenylxanthine) which has been shown to have affinity at rat A3 receptors. 2. Adenosine, R-PIA (N6-R-phenylisopropyl adenosine), CPA (N6-cyclopentyladenosine) and NECA (5'-N-ethylcarboxamidoadenosine) all elicited relaxant responses in the phenylephrine pre-contracted rat isolated aorta with the following potency order (p[A50] values in parentheses): NECA (7.07 +/- 0.11) > R-PIA (5.65 +/- 0.10) > CPA (5.05 +/- 0.12) > adenosine (4.44 +/- 0.12). 3. 8-SPT (10-100 microM) caused parallel rightward shifts of the E/[A] curves to NECA (pKB = 5.23 +/- 0.16). A smaller rightward shift of E/[A] curves to CPA was observed (pA2 = 4.85 +/- 0.17). However, no significant shifts of E/[A] curves to either adenosine or R-PIA were observed. 4. In the absence of endothelium E/[A] curves to NECA and CPA were right-shifted compared to controls. However, removal of the endothelium did not produce a substantial shift of adenosine E/[A] curves, and E/[A] curves to R-PIA were unaffected by removal of the endothelium. 5. In the presence of L-NAME (100 microM) E/[A] curves to NECA and CPA were right-shifted. However, no further shift of the CPA E/[A] curve was obtained when 8-SPT (50 microM) was administered concomitantly. The locations of curves to R-PIA and adenosine were unaffected by L-NAME (100 microM). 6. In the presence of PD 115,199 (0.1 microM) a parallel rightward shift of NECA E/[A] curves was observed (pA2 = 7.50 +/- 0.19). PD 115,199 (0.1 and 1 microM) gave smaller rightward shifts of E/[A] curves to R-PIA and CPA, but E/[A] curves to adenosine were not significantly shifted in the presence of PD 115,199 (0.1 or 1 microM). 7. The presence of ZM 241385 (3 nM-0.3 microM) caused parallel rightwad shifts of NECA E/[A] curves (pKB = 8.73 +/- 0.11). No significant shifts of E/[A] curves to adenosine, CPA or R-PIA were observed in the presence of 0.1 microM ZM 241385. 8. CGS 21680 (1 microM) elicited a relaxant response equivalent to approximately 40% of the NECA maximum response. In the presence of this concentration of CGS 21680, E/[A] curves to NECA were right-shifted in excess of 2-log units, whereas E/[A] curves to R-PIA were not significantly shifted. 9. BWA1433 (100 microM) caused a small but significant right-shift of the E/[A] curve to R-PIA yielding a pA2 estimate of 4.1 IB-MECA (N6-(3-iodo-benzyl)adenosine-5(1)-N-methyl uronamide) elicited relaxant responses which were resistant to blockade by 8-SPT (p[A]50 = 5.26 +/- 0.13). 10. The results suggest that whereas relaxations to NECA (10 nM-1 microM) are mediated via adenosine A2a receptors, which are located at least in part on the endothelium, R-PIA and CPA may activate A2b receptors on the endothelium and an additional, as yet undefined site, which is likely to be located on the smooth muscle and which is not susceptible to blockade by 8-SPT, PD 115,199 or ZM 241385. This site is unlikely to be an A3 receptor since the very small shift obtained in the presence of BWA1433 (100 microM), and the low potency of IB-MECA is not consistent with the affin

Manifestations of virus-specific antigens in virus-induced tumor cells. Theoretical and practical considerations.

'Moral panics' and asylum seekers.

Treatment of lysosomal storage disorders: Cell therapy and gene therapy

A novel quantum-inspired genetic algorithm for a weekly university scheduling optimization

Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Eccentricity and spin-orbit misalignment in short-period stellar binaries as a signpost of hidden tertiary companions

Characterization and partial purification of a lipase from Pseudomonas aeruginosa.

Adenosine antagonists as potential therapeutic agents

Medicinal chemistry of adenosine A3 receptor ligands

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

Species dependence of A3 adenosine receptor pharmacology and function

Metals, orthopaedic implants, and risk of cancer

Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors

Strain-related differences in adenosine receptor density and in behavioral sensitivity to adenosine analogs in mice

Postoperative cognitive decline: where art tau?

Neuroleptic Malignant Syndrome (NMS): What are the Genetic Factors?

Influence of diazepam, alpidem, zolpidem and zopiclone, on the response to adenosine of the guinea pig isolated trachea

A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity

Activation of multiple sites by adenosine analogues in the rat isolated aorta